Janice Morrow
Nurse Practitioner · West Columbia, SCNPI 1568572139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 671 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- plus $3K from 14 others
What the payments were for
- Food & beverage$12,46098%
- Education$2032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 148 | $1,952 |
| Neurocrine Biosciences, Inc. | 84 | $1,712 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 64 | $1,690 |
| AbbVie | 144 | $1,606 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,537 |
| Alkermes, Inc. | 36 | $1,152 |
| Johnson & Johnson | 42 | $984 |
| Vanda Pharmaceuticals Inc. | 37 | $659 |
| Indivior Inc. | 24 | $340 |
| E.r. Squibb & Sons, L.L.C. | 11 | $338 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $173 |
| Idorsia Pharmaceuticals US Inc | 2 | $131 |
| Lundbeck LLC | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Eisai Inc. | 3 | $57 |
| Merck | 3 | $47 |
| Noven Therapeutics, LLC | 3 | $36 |
| Tris Pharma Inc | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$908
- CAPLYTA$590
- ARISTADA$500
- INGREZZA$475
- VRAYLAR$458
- REXULTI$367
- UZEDY$344
- Fanapt$237
- INVEGA SUSTENNA$125
- ARISTADA INITIO$125
- QUVIVIQ$125
- ABILIFY MAINTENA$124
- COBENFY$117
How this compares
$12,663 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 29 | $159,578 |
| IngrezzaValbenazine Tosylate | 16 | $138,028 |
| Invega SustennaPaliperidone Palmitate | 32 | $91,836 |
| RexultiBrexpiprazole | 31 | $55,952 |
| CaplytaLumateperone Tosylate | 22 | $39,102 |
| VraylarCariprazine Hcl | 25 | $34,337 |
| TrintellixVortioxetine Hydrobromide | 35 | $19,781 |
| Paliperidone ErPaliperidone | 16 | $3,556 |
| Clozapine | 32 | $3,294 |
| Duloxetine Hcl | 103 | $2,550 |
| Quetiapine Fumarate | 152 | $2,231 |
| Fluphenazine Hcl | 18 | $1,761 |
| Aripiprazole | 52 | $1,746 |
| Risperidone | 53 | $1,239 |
| Buspirone Hcl | 73 | $1,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,952 | $159,57829 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,712 | $138,02816 claims |
| Johnson & JohnsonInvega Sustenna | $984 | $91,83632 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,537 | $55,95231 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,690 | $39,10222 claims |
| AbbVieVraylar | $1,606 | $34,33725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $19,78135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in West Columbia
- Margaret JohnsonWest Columbia$15K
- Merritt StevensonWest Columbia$8K
- Mallory AndersonWest Columbia$7K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.